% | $
Quotes you view appear here for quick access.

Rexahn Pharmaceuticals, Inc. Message Board

  • luiirigi5aaa luiirigi5aaa Oct 3, 2013 1:59 PM Flag

    More people need to know about this stock now

    "...The return of the license from TEVA can only be a benefit. Phased trials for RX-3117 will continue with a likely candidate being pancreatic cancer that is hard to treat and attracting the attention of major pharma companies like Merck & Co. (MRK) and Celgene Corp. (CELG). The global pancreatic cancer market is expected to rise to $1.2 billion within two years, and with unsatisfactory treatment options being studied among just a handful of competitors, other, more suitable partners could soon take an active interest in Rexahn and its revolutionary compound.

    The foremost risk facing Rexahn is loss of a deep-pocketed partner; however, the company has $15.7 million in cash to bring the company through a number of clinical developments, and a prestigious partner in the University of Maryland for which it is developing RX-21101, a re-engineered form of Taxotere for solid tumors. Other more common risks are enrollment for clinical trials and FDA delays. So far, Rexahn appears to have a favorable, expedited relationship with the FDA as evidenced by its Orphan Drug status for several compound indications,

    Rexahn has a platform for over a dozen drugs in targeted tumor therapy, representing billions of potential revenue dollars so that only a small percentage of market share would result in strong licensed sales for the company. Big pharmaceutical firms like Teva are proving that the cancer business is better served by younger, more dynamic companies, and in this light, I believe Rexahn will prevail as a leader in new cancer therapies."

    Above taken from recent "Seeking Alpha" report about RNN.
    Read the entire report, click onto RNN headlines on Yahoo Finance and look for Seeking Alpha report.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.7242+0.0142(+2.00%)May 27 4:00 PMEDT